BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer

References

• Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Nat Clin Pract Oncol 2007; 4:578 - 90; http://dx.doi.org/10.1038/ncponc0930; PMID: 17898808
   PubMedGoogle Scholar
• Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 2012; 12:68 - 78; http://dx.doi.org/10.1038/nrc3181; PMID: 22193408
   PubMed Web of Science ®Google Scholar
• Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010; 28:375 - 9; http://dx.doi.org/10.1200/JCO.2008.20.7019; PMID: 20008645
   PubMed Web of Science ®Google Scholar
• Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28:1145 - 53; http://dx.doi.org/10.1200/JCO.2009.22.4725; PMID: 20100965
   PubMed Web of Science ®Google Scholar
• Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011; 306:1557 - 65; http://dx.doi.org/10.1001/jama.2011.1456; PMID: 21990299
   PubMed Web of Science ®Google Scholar
• Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, et al, EMBRACE, kConFab Investigators, Cancer Genome Atlas Research Network. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012; 307:382 - 90; http://dx.doi.org/10.1001/jama.2012.20; PMID: 22274685
   PubMed Web of Science ®Google Scholar
• Kang J, D’Andrea AD, Kozono D. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. J Natl Cancer Inst 2012; 104:670 - 81; http://dx.doi.org/10.1093/jnci/djs177; PMID: 22505474
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123 - 34; http://dx.doi.org/10.1056/NEJMoa0900212; PMID: 19553641
   PubMed Web of Science ®Google Scholar
• Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28:2512 - 9; http://dx.doi.org/10.1200/JCO.2009.26.9589; PMID: 20406929
   PubMed Web of Science ®Google Scholar
• Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376:245 - 51; http://dx.doi.org/10.1016/S0140-6736(10)60893-8; PMID: 20609468
   PubMed Web of Science ®Google Scholar
• Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012; 30:372 - 9; http://dx.doi.org/10.1200/JCO.2011.36.9215; PMID: 22203755
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366:1382 - 92; http://dx.doi.org/10.1056/NEJMoa1105535; PMID: 22452356
   PubMed Web of Science ®Google Scholar
• Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 2012; 13:679 - 92; http://dx.doi.org/10.1038/nrg3270; PMID: 22945394
   PubMed Web of Science ®Google Scholar
• Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343:1350 - 4; http://dx.doi.org/10.1056/NEJM200011093431901; PMID: 11070098
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352:997 - 1003; http://dx.doi.org/10.1056/NEJMoa043331; PMID: 15758010
   PubMed Web of Science ®Google Scholar
• Bleeker FE, Molenaar RJ, Leenstra S. Recent advances in the molecular understanding of glioblastoma. J Neurooncol 2012; 108:11 - 27; http://dx.doi.org/10.1007/s11060-011-0793-0; PMID: 22270850
   PubMed Web of Science ®Google Scholar
• Catteau A, Harris WH, Xu CF, Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 1999; 18:1957 - 65; http://dx.doi.org/10.1038/sj.onc.1202509; PMID: 10208417
   PubMed Web of Science ®Google Scholar
• Magdinier F, Ribieras S, Lenoir GM, Frappart L, Dante R. Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region. Oncogene 1998; 17:3169 - 76; http://dx.doi.org/10.1038/sj.onc.1202248; PMID: 9872332
   PubMed Web of Science ®Google Scholar
• Rice JC, Massey-Brown KS, Futscher BW. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene 1998; 17:1807 - 12; http://dx.doi.org/10.1038/sj.onc.1202086; PMID: 9778046
   PubMed Web of Science ®Google Scholar
• Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92:564 - 9; http://dx.doi.org/10.1093/jnci/92.7.564; PMID: 10749912
   PubMed Web of Science ®Google Scholar
• Esteller M, Fraga MF, Guo M, Garcia-Foncillas J, Hedenfalk I, Godwin AK, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 2001; 10:3001 - 7; http://dx.doi.org/10.1093/hmg/10.26.3001; PMID: 11751682
   PubMed Web of Science ®Google Scholar
• Grushko TA, Dignam JJ, Das S, Blackwood AM, Perou CM, Ridderstråle KK, et al. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res 2004; 10:499 - 507; http://dx.doi.org/10.1158/1078-0432.CCR-0976-03; PMID: 14760071
   PubMed Web of Science ®Google Scholar
• Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE. Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 2002; 94:61 - 7; http://dx.doi.org/10.1093/jnci/94.1.61; PMID: 11773283
   PubMed Web of Science ®Google Scholar
• Ibanez de Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 2004; 64:6476 - 81; http://dx.doi.org/10.1158/0008-5472.CAN-04-1529; PMID: 15374957
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474:609 - 15; http://dx.doi.org/10.1038/nature10166; PMID: 21720365
   PubMed Web of Science ®Google Scholar
• Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001; 344:539 - 48; http://dx.doi.org/10.1056/NEJM200102223440801; PMID: 11207349
   PubMed Web of Science ®Google Scholar
• Veeck J, Ropero S, Setien F, Gonzalez-Suarez E, Osorio A, Benitez J, et al. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol 2010; 28:e563 - 4, author reply e565-6; http://dx.doi.org/10.1200/JCO.2010.30.1010; PMID: 20679605
   PubMed Web of Science ®Google Scholar
• Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 2011; 103:334 - 46; http://dx.doi.org/10.1093/jnci/djq509; PMID: 21183737
   PubMed Web of Science ®Google Scholar